Luvometinib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Pediatric patients 2 years and older with Langerhans cell histiocytosis (LCH) after... (CN)

This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also in development:Non-Small Cell Lung Cancer · Phase 2 · investigational in the US

Also approved (2)
CN
  • Pediatric patients 2 years and older with Langerhans cell histiocytosis (LCH) after systemic therapyfosunpharma.com
  • Adult patients with Langerhans cell histiocytosis (LCH) and histiocytic neoplasms; pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) with symptomatic plexiform neurofibromas (PN) not amenable to complete resection
    fosunpharma.com
Product first approved 2025Outside this platform's coverage

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Glioma
Other / comorbidity
NCT05913037 · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
2023-06-20 – 2026-06-30 · Neurofibromatosis 1, Plexiform Neurofibroma, NF1
What this study did
Phase 2 (6)
Non-Small Cell Lung Cancer
Other / comorbidity
NCT07713745 · Beijing Tiantan Hospital
2026-07-18 – 2036-12-31 · Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma, NF2-related Schwannomatosis, NF2
What this study did
NCT07728201 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2026-06-30 – 2030-06-30 · Langerhans Cell Histiocytosis
What this study did
NCT05997602 · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
2023-09-28 – 2027-05-14 · Langerhans Cell Histiocytosis, LCH
What this study did
NCT06913725 · Xuanwu Hospital, Beijing
2025-02-24 – 2026-09-30 · Brain Arteriovenous Malformations
What this study did
NCT06553365 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-08-15 – 2026-07-31 · Nerve Sheath Tumor
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT07708285 · Beijing Tiantan Hospital
2026-07-31 – 2029-12-31 · NF2-related Schwannomatosis, NF2, Neurofibromatosis Type 2, Vestibular Schwannoma, Meningioma
What this study did
NCT07024394 · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
2025-06-12 – 2029-09-23 · Neurofibromatosis 1, Plexiform Neurofibroma, NF1
What this study did
NCT04954001 · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
2021-03-26 – 2025-03-30 · Neurofibromatosis 1, Plexiform Neurofibroma, NF1
What this study did
Phase 1 (1)
Other / comorbidity
NCT03932253 · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
2019-03-21 – 2024-04-30 · Melanoma
What this study did
Early phase / not applicable (2)
Other / comorbidity
NCT07371182 · West China Second University Hospital
2026-06-19 – 2030-12-31 · Langerhans Cell Histiocytosis (LCH)
What this study did
NCT07431060 · West China Second University Hospital
2026-02-13 – 2030-12-31 · Langerhans Cell Histiocytosis (LCH)
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 3 of them ahead of this one.

This drug's own stage for Glioma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Luvometinib: this drugPhase 3Small moleculeMEK1/2not yet gradedNo reviewed efficacy summary in this indication
Cobimetinib
Approved(overall)
Small moleculeMEK1/2
Reliable signal(overall)
No reviewed efficacy summary in this indication
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)not yet gradedNo reviewed efficacy summary in this indication
DordaviproneApprovedSmall moleculeMitochondrial caseinolytic protease P (ClpP), Dopamine D2 receptorWeak signalNo reviewed efficacy summary in this indication
TemozolomideApprovedSmall moleculeDNA alkylation (O6-guanine)Partial signal
NCT00626990: Overall survival: adjuvant temozolomide vs none, median 82.3 vs 46.9 months, hazard ratio 0.64 (95% CI 0.52 to 0.79), p<0.0001; concurrent temozolomide vs none, 66.9 vs 60.4 months, hazard ratio 0.97 (95% CI 0.73 to 1.28), p=0.76 (CT.gov posted results).
TovorafenibApprovedSmall moleculeKinase InhibitorWeak signalNo reviewed efficacy summary in this indication
TrametinibApprovedSmall moleculeMEK1/2not yet gradedNo reviewed efficacy summary in this indication
SafusidenibPhase 3Small moleculeMutant IDH1not yet gradedNo reviewed efficacy summary in this indication
Abemaciclib (Verzenio)Phase 2Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
OlutasidenibPhase 2Small moleculeMutant IDH1not yet gradedNo reviewed efficacy summary in this indication
CrelosidenibPhase 1Small moleculeMutant IDH1 and IDH2not yet gradedNo reviewed efficacy summary in this indication
VebreltinibPhase 1Small moleculeMETnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Luvometinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
April 2027 (1)
Phase 3GliomaNot yet recruiting
Est. primary completion 2027-04-30 · NCT07004075 · CT.gov ↗
What to watch
2028 (2)
July 2028 (1)
Phase 2Langerhans Cell HistiocytosisNot yet recruiting
Est. primary completion 2028-07-31 · NCT07728201 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1/2NF2-related Schwannomatosis, NF2, Neurofibromatosis Type 2, Vestibular Schwannoma, MeningiomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07708285 · CT.gov ↗
What to watch
2029 (2)
June 2029 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-06 · NCT07562581 · CT.gov ↗
What to watch
September 2029 (1)
Phase 1/2Neurofibromatosis 1, Plexiform Neurofibroma, NF1Not yet recruiting
Est. primary completion 2029-09-23 · NCT07024394 · CT.gov ↗
What to watch
2030 (2)
December 2030 (2)
Early phase / not applicableLangerhans Cell Histiocytosis (LCH)Recruiting
Est. primary completion 2030-12-31 · NCT07371182 · CT.gov ↗
What to watch
Early phase / not applicableLangerhans Cell Histiocytosis (LCH)Recruiting
Est. primary completion 2030-12-31 · NCT07431060 · CT.gov ↗
What to watch
2036 (1)
June 2036 (1)
Phase 2Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma, NF2-related Schwannomatosis, NF2Not yet recruiting
Est. primary completion 2036-06-01 · NCT07713745 · CT.gov ↗
What to watch

See the full readout calendar ↗